ADRENOMEDULLİN VE DİYABET

Adrenomedullin (ADM) son dönemde keşfedilen, çok fonksiyonu olan bir peptiddir. Karakteristiketkileri arasında vazodilatör etkisi ve hipotansif özellikleri yer almaktadır. Farklı organlardayaygın bir üretim ve ekspresyonunun olduğu düşünüldüğünde ADM, çeşitli biyolojik sistemlerdeotokrin, endokrin ya da parakrin bir mediyatör olarak rol oynayabilir. Plazma ADM düzeylerininçeşitli hastalıklarda artması, ADM’nin hastalık durumlarında olası bir modülatör rolüne işaretetmektedir. Kardiyovasküler hastalıklarda ve diyabette plazma ADM düzeyleri artmaktadır vebu durum hep tip 1 hem de tip 2 diyabette gözlenen diyabetik komplikasyonlar ile ilişkilidir. Kardiyovaskülerhastalıklardaki bulgulardan farklı olarak, diyabette gözlenen ADM düzeylerindekibu artış, tam olarak açıklanamamıştır. Bu yüzden son dönemdeki araştırmalar ADM ve diyabetarasındaki ilişkiye yoğunlaşmıştır. ADM’nin glukoz metabolizması ve insülin dengesinin sağlanmasındabir rol oynadığının gösterilmesi, ADM-diyabet ilişkisine dair bir ipucu oluşturmaktadır.Bu derlemede ADM’nin diyabetteki rolüne dair yapılan çalışmalar üzerinde durulmuştur

Adrenomedullin And Diabetes

Adrenomedullin (ADM) is a novel peptide that has a wide range of functional effects discovered in recent years. ADM has vasodilator and hypotensive effects. Considering widespread production and expression of ADM in different tissues, ADM could play as an endocrin, paracrin or otocrin roles in different biological systems. Increasing of plasma ADM levels in different pathological diseases, indicate possible modulator role of ADM in these diseases. It was shown that plasma ADM levels were increased in cardiovascular diseases and diabetes and is associated with diabetic complications in both type 1 and 2 diabetes. But, different from the findings in cardiovascular diseases, the definition and significance for such an increament is not clear. Therefore, recent studies has been concentrated on the association between ADM and diabetes. Showing ADM plays a role in glucose metabolism and insulin balance, these evidence might obtain clue on the involvement of ADM in diabetes. In this review, we try to summary the existing studies about the role of ADM in diabetes.

PDF

___

Wong HK, Ong KL, Leung RY, Lam TH, Thomas GN, Lam KS, Cheung BM. A single nucleotide polymorphism of interleukin-6 gene is related to plasma adrenomedullin levels. Clinical endocrinology. 2013;79(4):504-9.
Wong HK, Ong KL, Leung RY, Cheung TT, Xu A, Lam TH, Lam KS, Cheung BM. Plasma level of adrenomedullin is influenced by a single nucleotide polymorphism in the adiponectin gene. PloS one. 2013;8(8):e70335.
Cheung BM, Ong KL, Tso AW, Leung RY, Cherny SS, Sham PC, Lam TH, Lam KS. Plasma adrenomedullin level is related to a single nucleotide polymorphism in the adrenomedullin gene. European journal of endocrinology / European Federation of Endocrine Societies. 2011;165(4):571-7.
Ong KL, Tso AW, Leung RY, Cherny SS, Sham PC, Lam TH, Cheung BM, Lam KS. A genetic variant in the gene encoding adrenomedullin predicts the development of dysglycemia over 6.4 years in Chinese. Clinica chimica acta; international journal of clinical chemistry. 2011;412(3-4):353-7.
Xing G, Shimosawa T, Ogihara T, Matsui H, Itakura K, Qingyou X, Asano T, Ando K, Fujita T. Angiotensin II-induced insulin resistance is enhanced in adrenomedullin-deficient mice. Endocrinology. 2004;145(8):3647-51.
Katsuki A, Sumida Y, Urakawa H, Gabazza EC, Maruyama N, Morioka K, Kitagawa N, Hori Y, Nakatani K, Yano Y, Adachi Y. Increased oxidative stress is associated with elevated plasma levels of adrenomedullin in hypertensive patients with type 2 diabetes. Diabetes care. 2003;26(5):1642-3.
Katsuki A, Sumida Y, Gabazza EC, Murashima S, Urakawa H, Morioka K, Kitagawa N, Tanaka T, Araki-Sasaki R, Hori Y, Nakatani K, Yano Y, Adachi Y. Acute hyperinsulinemia is associated with increased circulating levels of adrenomedullin in patients with type 2 diabetes mellitus. European journal of endocrinology / European Federation of Endocrine Societies. 2002;147(1):71-5.
Lim SC, Morgenthaler NG, Subramaniam T, Wu YS, Goh SK, Sum CF. The relationship between adrenomedullin, metabolic factors, and vascular function in individuals with type 2 diabetes. Diabetes care. 2007;30(6):1513-9.
Martinez A, Elsasser TH, Bhathena SJ, Pio R, Buchanan TA, Macri CJ, Cuttitta F. Is adrenomedullin a causal agent in some cases of type 2 diabetes? Peptides. 1999;20(12):1471-8.
Nakamura T, Honda K, Ishikawa S, Kitamura K, Eto T, Saito T. Plasma adrenomedullin levels in patients with non-insulin dependent diabetes mellitus: close relationships with diabetic complications. Endocrine journal. 1998;45(2):241-6.
Kato J, Tsuruda T, Kita T, Kitamura K, Eto T. Adrenomedullin: a protective factor for blood vessels. Arteriosclerosis, thrombosis, and vascular biology. 2005;25(12):2480-7.
Shimosawa T, Shibagaki Y, Ishibashi K, Kitamura K, Kangawa K, Kato S, Ando K, Fujita T. Adrenomedullin, an endogenous peptide, counteracts cardiovascular damage. Circulation. 2002;105(1):106-11.
Kato H, Shichiri M, Marumo F, Hirata Y. Adrenomedullin as an autocrine/paracrine apoptosis survival factor for rat endothelial cells. Endocrinology. 1997;138(6):2615-20.
Ruzicska E, Toth M, Tulassay Z, Somogyi A. Adrenomedullin and diabetes mellitus. Diabetes/metabolism research and reviews. 2001;17(5):321-9.
Hirayama N, Kitamura K, Imamura T, Kato J, Koiwaya Y, Eto T. Secretion and clearance of the mature form of adrenomedullin in humans. Life sciences. 1999;64(26):2505-9.
Garcia-Unzueta MT, Montalban C, Pesquera C, Berrazueta JR, Amado JA. Plasma adrenomedullin levels in type 1 diabetes. Relationship with clinical parameters. Diabetes care. 1998;21(6):999- 1003.
Ishimitsu T, Nishikimi T, Saito Y, Kitamura K, Eto T, Kangawa K Matsuo H, Omae T, Matsuoka H. Plasma levels of adrenomedullin, a newly identified hypotensive peptide, in patients with hypertension and renal failure. The Journal of clinical investigation. 1994;94(5):2158-61.
Hiragushi K, Wada J, Eguchi J, Matsuoka T, Yasuhara A, Hashimoto I, Yamashita T, Hida K, Nakamura Y, Shikata K, Minamino N, Kangawa K, Makino H. The role of adrenomedullin and receptors in glomerular hyperfiltration in streptozotocin-induced diabetic rats. Kidney international. 2004;65(2):540-50.
Kinoshita H, Kato K, Kuroki M, Nakamura S, Kitamura K, Hisanaga S, Fujimoto S, Eto T. Plasma adrenomedullin levels in patients with diabetes. Diabetes care. 2000;23(2):253-4.
Liao SB, Wong PF, Cheung BM, Tang F. Effects of adrenomedullin on tumour necrosis factor alpha, interleukins, endothelin-1, leptin, and adiponectin in the epididymal fat and soleus muscle of the rat. Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme. 2013;45(1):31-7.
Tang F, Hwang IS, Wong MP, Li YY. Adrenomedullin gene expression and peptide levels in the heart and blood vessels of streptozotocin-diabetic rats. Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme. 2007;39(1):3-8.
Hayashi M, Shimosawa T, Fujita T. Hyperglycemia increases vascular adrenomedullin expression. Biochemical and biophysical research communications. 1999;258(2):453-6.
Bunton DC, Petrie MC, Hillier C, Johnston F, McMurray JJ. The clinical relevance of adrenomedullin: a promising profile? Pharmacology & therapeutics. 2004;103(3):179-201.
Wu JT. Review of diabetes: identification of markers for early detection, glycemic control, and monitoring clinical complications. Journal of clinical laboratory analysis. 1993;7(5):293-300.
Tahrani AA, Piya MK, Kennedy A, Barnett AH. Glycaemic control in type 2 diabetes: targets and new therapies. Pharmacology & therapeutics. 2010;125(2):328-61.
Tsuchida T, Ohnishi H, Tanaka Y, Mine T, Fujita T. Inhibition of stimulated amylase secretion by adrenomedullin in rat pancreatic acini. Endocrinology. 1999;140(2):865-70.
Zudaire E, Cuttitta F, Martinez A. Regulation of pancreatic physiology by adrenomedullin and its binding protein. Regulatory peptides. 2003;112(1-3):121-30.
Lopez J, Cuesta N. Adrenomedullin as a pancreatic hormone. Microscopy research and technique. 2002;57(2):61-75.
Poyner DR, Sexton PM, Marshall I, Smith DM, Quirion R, Born W, Muff R, Fischer JA, Foord SM. International Union of Pharmacology. XXXII. The mammalian calcitonin gene-related peptides, adrenomedullin, amylin, and calcitonin receptors. Pharmacological reviews. 2002;54(2):233-46.
Hagner S, Stahl U, Knoblauch B, McGregor GP, Lang RE. Calcitonin receptor-like receptor: identification and distribution in human peripheral tissues. Cell and tissue research. 2002;310(1):41-50.
Owji AA, Smith DM, Coppock HA, Morgan DG, Bhogal R, Ghatei MA, Bloom SR. An abundant and specific binding site for the novel vasodilator adrenomedullin in the rat. Endocrinology. 1995;136(5):2127-34.
Cheung BM, Tang F. Adrenomedullin: exciting new horizons. Recent patents on endocrine, metabolic & immune drug discovery. 2012;6(1):4-17.
Chun TH, Itoh H, Ogawa Y, Tamura N, Takaya K, Igaki T, Yamashita J, Doi K, Inoue M, Masatsugu K, Korenaga R, Ando J, Nakao K. Shear stress augments expression of C-type natriuretic peptide and adrenomedullin. Hypertension. 1997;29(6):1296-302.
Sugo S, Minamino N, Shoji H, Kangawa K, Kitamura K, Eto T, Matsuo H. Interleukin-1, tumor necrosis factor and lipopolysaccharide additively stimulate production of adrenomedullin in vascular smooth muscle cells. Biochemical and biophysical research communications. 1995;207(1):25-32.
Wong HK, Tang F, Cheung TT, Cheung BM. Adrenomedullin and diabetes. World journal of diabetes. 2014;5(3):364-71.
Nishikimi T, Yoshihara F, Mori Y, Kangawa K, Matsuoka H. Cardioprotective effect of adrenomedullin in heart failure. Hypertension research : official journal of the Japanese Society of Hypertension. 2003;26 Suppl:S121-7.
Marutsuka K, Hatakeyama K, Sato Y, Yamashita A, Sumiyoshi A, Asada Y. Immunohistological localization and possible functions of adrenomedullin. Hypertension research : official journal of the Japanese Society of Hypertension. 2003;26 Suppl:S33-40.
Nishikimi T, Kitamura K, Saito Y, Shimada K, Ishimitsu T, Takamiya M, Kangawa K, Matsuo H, Eto T, Omae T, Matsuoka H. Clinical studies on the sites of production and clearance of circulating adrenomedullin in human subjects. Hypertension. 1994;24(5):600-4.
Kitamura K, Kangawa K, Eto T. Adrenomedullin and PAMP: discovery, structures, and cardiovascular functions. Microscopy research and technique. 2002;57(1):3-13.
Julian M, Cacho M, Garcia MA, Martin-Santamaria S, de PascualTeresa B, Ramos A, Martínez A, Cuttitta F. Adrenomedullin: a new target for the design of small molecule modulators with promising pharmacological activities. European journal of medicinal chemistry. 2005;40(8):737-50.
Sugo S, Minamino N, Kangawa K, Miyamoto K, Kitamura K, Sakata J, Eto T, Matsuo H. Endothelial cells actively synthesize and secrete adrenomedullin. Biochem Biophys Res Commun. 1994;201(3):1160-6.
Ichiki Y, Kitamura K, Kangawa K, Kawamoto M, Matsuo H, Eto T. Distribution and characterization of immunoreactive adrenomedullin in human tissue and plasma. FEBS letters. 1994;338(1):6-10.
Sakata J, Shimokubo T, Kitamura K, Nakamura S, Kangawa K, Matsuo H, Eto T. Molecular cloning and biological activities of rat adrenomedullin, a hypotensive peptide. Biochem Biophys Res Commun. 1993;195(2):921-7.
Kitamura K, Sakata J, Kangawa K, Kojima M, Matsuo H, Eto T. Cloning and characterization of cDNA encoding a precursor for human adrenomedullin. Biochem Biophys Res Commun.. 1993;194(2):720-5.
Kitamura K, Kangawa K, Kawamoto M, Ichiki Y, Nakamura S, Matsuo H, Eto T. Adrenomedullin: a novel hypotensive peptide isolated from human pheochromocytoma. Biochem Biophys Res Commun. 1993;192(2):553-60.